Search research articles
Contact Us
Filters
Showing results (141-150 of 210) with videos related to
Page
of 21
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 15, 2015
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms
Brady L Stein, Jason Gotlib, Murat Arcasoy, et al.
The New England Journal of Medicine
|
March 2, 2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Theranostics
|
September 15, 2020
Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts
Peter Valent, Cem Akin, Karin Hartmann, et al.
The Journal of Allergy and Clinical Immunology
|
June 21, 2020
Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
Peter Valent, Cem Akin, Patrizia Bonadonna, et al.
Nature Medicine
|
December 7, 2021
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
Jason Gotlib, Andreas Reiter, Deepti H Radia, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
March 28, 2022
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice
Peter Valent, Karin Hartmann, Juliana Schwaab, et al.
Cancer Cell
|
June 5, 2003
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease
Jan Cools, Elizabeth H Stover, Christina L Boulton, et al.
Leukemia Research
|
January 11, 2007
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)
Ruben A Mesa, Srdan Verstovsek, Francisco Cervantes, et al.
Haematologica
|
September 17, 2013
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
February 10, 2019
Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
Peter Valent, Cem Akin, Patrizia Bonadonna, et al.
Page
of 21
Search research articles
Search
Showing results (141-150 of 210) with videos related to
Sort By:
Page
of 21
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 15, 2015
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms
Brady L Stein, Jason Gotlib, Murat Arcasoy, et al.
The New England Journal of Medicine
|
March 2, 2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Theranostics
|
September 15, 2020
Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts
Peter Valent, Cem Akin, Karin Hartmann, et al.
The Journal of Allergy and Clinical Immunology
|
June 21, 2020
Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
Peter Valent, Cem Akin, Patrizia Bonadonna, et al.
Nature Medicine
|
December 7, 2021
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
Jason Gotlib, Andreas Reiter, Deepti H Radia, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
March 28, 2022
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice
Peter Valent, Karin Hartmann, Juliana Schwaab, et al.
Cancer Cell
|
June 5, 2003
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease
Jan Cools, Elizabeth H Stover, Christina L Boulton, et al.
Leukemia Research
|
January 11, 2007
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)
Ruben A Mesa, Srdan Verstovsek, Francisco Cervantes, et al.
Haematologica
|
September 17, 2013
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
February 10, 2019
Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
Peter Valent, Cem Akin, Patrizia Bonadonna, et al.
Page
of 21